U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07035249) titled 'A Prospective Single-Arm Clinical Study of DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors' on June 15.
Brief Summary: To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.
Study Start Date: June 16
Study Type: INTERVENTIONAL
Condition:
DCSZ11
Solid Tumors
HNSCC
Intervention:
DRUG: DCSZ11
DCSZ11 combined with available standard treatment,DCSZ11 was adjusted per the dose-escalation design. In the initial dose cohort, three patients will be administered DCSZ11 600 mg every three weeks (Q3W); subsequently, the do...